Neogen Corporation reports developments tied to its food safety and animal safety businesses, including diagnostic tests, environmental monitoring products, veterinary products and related manufacturing operations. Company updates commonly cover foodborne pathogen detection, Listeria testing, AOAC method certification, Petrifilm manufacturing activity, and product quality or recall matters involving animal health products.
Neogen news also includes quarterly operating results, segment performance in Food Safety and Animal Safety, business transformation updates, leadership and compliance appointments, and governance matters. Its recurring disclosures connect scientific validation, manufacturing execution, customer markets and regulatory interactions across food safety, livestock, and pet health and wellness applications.
Neogen (NEOG) will participate in the 2026 UBS Global Healthcare Conference in Palm Beach Gardens, Florida, on Tuesday, November 10.
Neogen (NEOG) outlined a growth and margin-expansion strategy at its Investor Day, setting financial targets for fiscal year 2031. The company targets high-single-digit to low-double-digit total revenue growth, an adjusted gross margin in the high-50% range and a 30% adjusted EBITDA margin, a measure of earnings before interest, taxes, depreciation, amortization and certain adjustments. Its framework also includes a commitment to net leverage below 2.5 times.
Neogen plans to increase research and development investment by approximately 50% in FY2027, targeting approximately 5% of revenue by FY2031. It has reorganized its commercial model around integrated solutions and implemented strategic account management for its largest global food manufacturing clients. The company reports it is on track to manufacture saleable Petrifilm product and begin a planned multi-quarter transition to its Lansing manufacturing site starting in November 2026.
Neogen (NASDAQ: NEOG) reported fiscal 2027 first-quarter revenue of $222.8 million, up 6.5% from the prior-year quarter, and raised annual guidance. For the quarter ended August 31, 2026, core growth, excluding currency effects and recent divestitures and discontinued lines, was 8.1%. Food Safety revenue rose 7.4% to $163.2 million; Animal Safety rose 4.2% to $59.6 million.
Net loss was $11.9 million, or $0.05 per diluted share, versus $36.3 million net income a year earlier, when a business-sale gain lifted earnings. Adjusted EBITDA rose to $41.6 million from $35.5 million. Neogen now expects annual revenue of $885–$890 million and adjusted EBITDA of $181–$183 million. Operating cash flow was $12.9 million. The company expects its multi-quarter Petrifilm manufacturing transition to begin in November 2026. The Genomics sale to Zoetis remains subject to regulatory reviews, expected to conclude by the end of December 2026.
Neogen (NEOG) announced a collaboration with and an equity investment in Hinalea Imaging to develop digital food safety inspection solutions. The companies have worked together since 2025 to evaluate food safety applications for hyperspectral imaging, which captures information across wavelengths to assess characteristics conventional images may not reveal.
The partners plan to jointly develop food safety and quality inspection solutions. Neogen expects its investment and shared development costs to accelerate development of Hinalea’s technology for food safety applications. The planned solutions could improve inspection and testing workflows and help customers interpret results faster and more consistently. Both companies will continue evaluating where the technology can benefit customer workflows.
Neogen (NEOG) will release its first-quarter earnings after the market closes on October 6, 2026.
Company executives will host a webcast and conference call at 4:30 p.m. Eastern time to discuss the results. The live webcast will be available via Neogen’s Investor Relations webpage under “Events & Presentations,” and a replay of both the call and webcast will be accessible shortly after the event through the same site and dedicated replay phone lines.
Neogen (NEOG) will host an Investor Day on October 7, 2026, at 9 a.m. ET in New York City.
The event will focus on Neogen’s strategic transformation, including its commercial capabilities, innovation efforts, and operational excellence aimed at improving financial performance and long-term profitable growth. Senior executives, including the CEO, CFO and business unit leaders, will present and then take part in a Q&A session. A live webcast, presentation materials and a replay will be available on Neogen’s Investor Relations website.
Neogen (NASDAQ: NEOG) reported fiscal Q4 2026 revenue of $225.3 million, down 0.1% year over year, with core growth of 4.3%. Full-year 2026 revenue was $870.4 million, a decline of 2.7%, and core growth of 1.9%.
Q4 Food Safety revenue rose 3.1% (core +5.8%), led by Indicator Testing & Culture Media (+9.5%) and Bacterial & General Sanitation (+9.9%). Animal Safety revenue fell 8.2% but grew over 7% sequentially as supply issues eased. Q4 gross margin improved to 47.8% from 41.2%, with adjusted gross margin at 49.7%.
Neogen posted a Q4 net loss of $11.3 million (EPS $(0.05)), versus a $612.2 million loss a year ago. Q4 adjusted net income was $18.7 million (EPS $0.09). Adjusted EBITDA reached $45.4 million with a 20.2% margin. The company is progressing on its Petrifilm manufacturing transition and expects the first fully validated SKU by August 2026.
Neogen continues to work toward selling its global Genomics business to Zoetis for $160 million (about $140 million net, primarily for debt reduction). For FY27, it guides revenue to $880–$885 million and adjusted EBITDA to $180–$182 million, including estimated Genomics contributions, and Q1 FY27 revenue of $207–$209 million with adjusted EBITDA of about $37 million.
Neogen (NASDAQ: NEOG) will release its fourth-quarter fiscal year 2026 financial results before the market opens on Thursday, July 30, 2026. Company executives will host a webcast and conference call at 8:00 a.m. Eastern time to provide a financial overview and business update. Investors can access the call via toll-free and international dial-in numbers using Conference ID 741 914 740, or through the Investor Relations section of Neogen’s website, where a replay will be available after the event.
Neogen (NASDAQ: NEOG) expanded availability of FIFRA Section 2(ee) recommendations for Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol to support New World Screwworm response efforts.
Texas has approved these uses, and Neogen is making recommendations available in Florida to aid livestock and horse owners’ fly management programs.
Neogen (NASDAQ: NEOG) announced AOAC Performance Tested Methods℠ certification (No. 042604) for its Molecular Detection Assay - Listeria Right Now™, validating enrichment-free detection of viable and non-viable Listeria species on stainless steel.
The test delivers actionable results in about two hours, integrates with existing environmental monitoring workflows, and expands Neogen’s validated pathogen-detection portfolio.